louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03675984: Development of Exercise Protocol for Scoliosis Using Surface Electromyography(S-EMG)
Official title: Development of Exercise Protocol for Scoliosis Using Surface Electromyography(S-EMG)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Idiopathic Scoliosis
Keywords: surface EMG, cobb angle, exercise, Spinal Curvatures
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2018-09-18
Enrollment: 23
Sex: ALL
Minimum age (years): 8
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Annual evaluation after educating asymmetrical stabilization exercise. Cohort study.
Primary purpose: TREATMENT

Brief summary: There has been much effort in recent years to better understand the causes of idiopathic scoliosis (IS). Some studies suggested muscle imbalance as a cause of scoliosis based on asymmetric muscular activation. Surface electromyography can evaluate asymmetrical muscular weakness. Therefore, the peak amplitude values can be used to compare the side to side differences in paraspinal muscles. From these findings the investigators improve the exercise method of IS according to muscle weakness and curve pattern.

Detailed description: Design: Prospective study Setting: hospital rehabilitation department the investigators will check the muscular activation at bilateral paraspinal muscles with surface electromyography and curve type with simple radiography.

Intervention: After that the investigators educate asymmetrical stabilization exercise according to muscle weakness and curve pattern.

Main outcome measures: Cobb angle

Eligibility criteria: Inclusion Criteria:

* X-ray shows a cobb angle of 10 degrees or higher.
* Patients 8 and older.

Exclusion Criteria:

* Patients with spinal surgery
* Patients with scoliosis caused by cerebral palsy, muscle paralysis, polio, congenital spinal cord abnormalities, etc.
* Cobb angle less than 10 degrees and more than 40 degrees
* Patients with acute back pain

Primary outcomes:
measure: Cobb angle
timeFrame: through study completion, an average of 6 months
Secondary outcomes:
measure: Scoliosis Research Society-22(SRS-22)
timeFrame: through study completion, an average of 6 months
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Kyungji-do
Study officials:
References:
Clinical trial NCT02833584: Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dengue
Transaminitis
Keywords: Paracetamol
Lead sponsor: Phramongkutklao College of Medicine and Hospital
Sponsor class: OTHER
First posted: 2016-07-14
Enrollment: 123
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether regular dosage of paracetamol causes transaminitis (hepatitis) and evaluate its potency in the treatment of dengue infection.


Eligibility criteria: Inclusion Criteria:

* Patient age \>18 years
* Dengue infection diagnosed by NS1 antigen, Dengue immunoglobulin M antibody, or polymerase chain reaction
* Admitted to the hospital
* Written informed consent from patient or attending relative able to and willing to give informed consent

Exclusion Criteria:

* Other possible cause of fever other than dengue infection
* Pregnancy
* Unable to take medication
* Aminotransferase level above 3 times upper normal limit
* Allergy to paracetamol or tramadol
* Paracetamol indicated for condition other than dengue infection
* Critically ill patient who need ICU or invasive ventilation support
* History of cirrhosis
* Unable to comunicate

Primary outcomes:
measure: Proportion of subjects with abnormal serum transaminase levels on the last day of fever
timeFrame: Day 1-8
measure: Mean serum transaminase level
timeFrame: Day 1-8
measure: Mean change in serum transaminase levels
timeFrame: Day 1-8
Secondary outcomes:
measure: Body temperature
timeFrame: 8 days
measure: Duration of fever
timeFrame: 8 days
measure: Length of stay
timeFrame: 10 days
measure: Number of drug tablet used
timeFrame: 8 days
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Phramongkutklao College of Medicine and Hospital
city: Lopburi
country: Thailand
facility: Anandamahidol Hospital
city: Saraburi
country: Thailand
facility: Fort Adisorn Hospital
Study officials:
affiliation: Phramongkutklao College of Medicine and Hospital
name: Dhitiwat Changpradub, MD
role: STUDY_DIRECTOR
References:
citation: Vasikasin V, Rojdumrongrattana T, Chuerboonchai W, Siriwiwattana T, Thongtaeparak W, Niyasom S, Lertliewtrakool N, Jitsiri S, Changpradub D. Effect of standard dose paracetamol versus placebo as antipyretic therapy on liver injury in adult dengue infection: a multicentre randomised controlled trial. Lancet Glob Health. 2019 May;7(5):e664-e670. doi: 10.1016/S2214-109X(19)30032-4.
Clinical trial NCT03185884: Carbohydrates and Children
Official title: An Evaluation of Carbohydrates and Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Carbohydrate Metabolism
Lead sponsor: Abbott Nutrition
Sponsor class: INDUSTRY
First posted: 2017-06-14
Enrollment: 20
Sex: ALL
Minimum age (years): 9
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This study will evaluate the impact of test carbohydrate blends on fat and carbohydrate oxidation, glucose, insulin and hunger scores in pre-adolescent boys and girls.


Eligibility criteria: Inclusion Criteria:

* Male 9 -13 years of age, or female 9- 10 years of age
* Tanner stage 1
* Subject was born full term
* Subject was born normal weight
* Subject passes the Physical Activity Readiness Questionnaire
* Body mass index \>5th percentile and \<95th percentile for age and gender
* Subject has voluntarily signed and dated a youth assent document

Exclusion Criteria:

* History of metabolic. endocrine, or hyperactivity disorders
* Allergy or intolerance to any ingredient found in the study products
* Participation in a concomitant trial of a non-registered drug or that otherwise conflicts with this study

Primary outcomes:
measure: Energy Utilization
timeFrame: Study Visits 1 to 2 (1- 14 days)
Secondary outcomes:
measure: Hunger Assessment
timeFrame: Study Visits 1 to 2 (1- 14 days)
measure: Blood Measurements - Glucose
timeFrame: Study Visits 1 to 2 (1- 14 days)
measure: Blood Measurements - Insulin
timeFrame: Study Visits 1 to 2 (1- 14 days)
Other outcomes:
Locations:
city: Lincoln
country: United States
facility: University of Nebraska-Lincoln
state: Nebraska
Study officials:
affiliation: Abbott Nutrition
name: Vikkie Mustad, PhD
role: STUDY_CHAIR
References:
citation: Gillen ZM, Mustad VA, Shoemaker ME, Mckay BD, Leutzinger TJ, Lopez-Pedrosa JM, Rueda R, Cramer JT. Impact of slow versus rapid digesting carbohydrates on substrate oxidation in pre-pubertal children: A randomized crossover trial. Clin Nutr. 2021 Jun;40(6):3718-3728. doi: 10.1016/j.clnu.2021.05.004. Epub 2021 May 11.
citation: Shoemaker ME, Gillen ZM, Mckay BD, Leutzinger TJ, Mustad VA, Cramer JT. Endogenous versus exogenous carbohydrate oxidation measured by stable isotopes in pre-pubescent children plus 13C abundances in foods consumed three days prior. Metabol Open. 2020 Jul 15;7:100041. doi: 10.1016/j.metop.2020.100041. eCollection 2020 Sep.
Clinical trial NCT01945684: A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Spasticity
Stroke
Lead sponsor: Daewoong Pharmaceutical Co. LTD.
Sponsor class: INDUSTRY
First posted: 2013-09-18
Enrollment: 197
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Purpose: This study is a Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb(wrist, finger, elbow, thumb)Spasticity.


Eligibility criteria: Inclusion Criteria:

1. Male or female adult patients
2. ≥ 6 weeks since the last stroke

Exclusion Criteria:

1.Patients with diagnosed neuromuscular disorders such as Lamber-Eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis.

Primary outcomes:
measure: The change in MAS(Modified Ashworth Scale)grade for Wrist flexor
timeFrame: at 4 week
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: SMG-SNU Boramae Medical Center, 41, Borame-Gill, Dong Gjak-Gu
Study officials:
References:
Clinical trial NCT06525584: Ketamine Infusion as a Method of Cerebral Protection in Children
Official title: Ketamine Infusion in the Postoperative Period as a Method of Cerebral Protection in Children During Surgical Correction of Congenital Heart Defects
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Brain Injuries
Lead sponsor: Kemerovo State Medical University
Sponsor class: OTHER
First posted: 2024-07-29
Enrollment: 196
Sex: ALL
Minimum age (years): 1
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study is devoted to the use of ketamine infusion in a subanesthetic dose in the postoperative period in children after surgical correction of congenital heart defects in children.

Detailed description: The study will examine the safety and effectiveness for neuroprotection of subanesthetic doses of ketamine in the postoperative period in children undergoing operations to correct septal congenital heart defects using cardiopulmonary bypass.

Eligibility criteria: Inclusion Criteria:

* age from 1 to 60 months
* body weight from 3.5 to 20 kg
* planned surgical intervention to correct a congenital heart defect (atrial or ventricular septal defect) with CPBё
* the presence of informed consent for participation in the study signed by the child's legal representative

Exclusion Criteria:

* lack of informed consent of the patient and parents to participate in the study,
* emergency and urgent surgical interventions;
* the presence of clinically significant anemia;
* hypo-thermic during operation, episodes of desaturation in the perioperative period;
* the presence of another congenital heart diseases besides the atrial or ventricular septal defect, as well as their combination;
* a history of central nervous system diseases;
* an installed pacemaker;
* hemodynamic instability requiring preoperative pharmacological and/or mechanical support;
* any episodes of cerebrovascular accidents in the history or periop-erative period;
* the presence of a patient with severe concomitant diseases that worsen mental and somatic conditio;
* acute infection and exacerbation of chronic infection in the perioperative period;
* concomitant autoimmune diseases;
* the presence of malignant neoplasms;
* surgical complications in the postoperative period.

Primary outcomes:
measure: Biomarkers
timeFrame: 16 hours after operation
Secondary outcomes:
Other outcomes:
Locations:
city: Kemerovo
country: Russian Federation
facility: Artem Ivkin
state: Please Select
Study officials:
References:
Clinical trial NCT05602584: Effect of Immunophenotype on Prognosis of Sepsis
Official title: The Effect of Immunophenotype on Prognosis of Sepsis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sepsis
Septic Shock
Sepsis Syndrome
Keywords: Immunophenotype
Lead sponsor: Southeast University, China
Sponsor class: OTHER
First posted: 2022-11-02
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We investigate the patients with sepsis 3 diagnostic criteria were admitted to ICU; Aged 18 or above; Within 24 hours of diagnosis.

Brief summary: The popuse of this study is to assess the inflammatory immunophenotypes of sepsis patients are significantly correlated with prognosis, which may provide theoretical basis for precise immune regulation of sepsis.

Detailed description: The clinical characteristics and inflammatory/immune markers of sepsis patients were analyzed dynamically and followed up to one year after diagnosis. Through latent category analysis, cluster analysis and other inflammatory immunophenotypes, the clinical characteristics of different inflammatory immunophenotypes and their relationship with the long-term prognosis of sepsis were clarified.

Eligibility criteria: Inclusion Criteria:Patients with sepsis 3 diagnostic criteria were admitted to ICU; Aged 18 or above; Within 24 hours of diagnosis.

-

Exclusion Criteria:Malignant tumor; Autoimmune diseases; Diseases of the blood system; HIV infection; History of high-dose glucocorticoid use (hydrocortisone 200mg/d or other hormone with equivalent titer, more than one week); pregnancy

-

Primary outcomes:
measure: survival or death in 28 days
timeFrame: From date of randomization until the date of out of ICU or date of death from any cause, whichever came first, assessed up to 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Department of Critical Care , Zhong-da Hospital
state: Jiangsu
Study officials:
References:
Clinical trial NCT06797284: The Impact of Light, Electrical, and Magnetic Neuroregulation Interventions on Sleep-wake Disorders
Official title: The Impact of Light, Electrical, and Magnetic Neuroregulation Interventions on Sleep-wake Disorders
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Insomnia Chronic
Narcolepsy
REM Sleep Behavior Disorder
Lead sponsor: Second Affiliated Hospital of Soochow University
Sponsor class: OTHER
First posted: 2025-01-28
Enrollment: 20
Sex: ALL
Minimum age (years): 8
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Carry out precise and effective neuromodulation interventions, and develop new neuromodulation technologies for sleep disorders. Use phototherapy, transcranial electrical/magnetic stimulation and other therapies to conduct self-controlled intervention studies on insomnia, narcolepsy, and rapid eye movement sleep behavior disorder .


Eligibility criteria: Inclusion Criteria:

- Patients with insomnia, narcolepsy,and RBD that have been clearly diagnosed by specialists should sign the informed consent form.

Exclusion Criteria:

1. Patients with major neurological diseases such as multi-infarct dementia, Huntington\&#39;s disease, normal pressure hydrocephalus, brain tumors, progressive supranuclear palsy, epilepsy, subdural hematoma, multiple sclerosis, or those who have sustained neurological dysfunction or known structural brain abnormalities after significant head trauma are excluded.
2. A history of major depressive disorder or bipolar disorder within the past year, as defined in DSM-IV criteria. A history of schizophrenia (meeting DSM-IV criteria).
3. History of severe drug or alcohol abuse within the past year;
4. Any significant systemic illness or unstable medical condition that may make it difficult to comply with the protocol, such as severe autoimmune diseases or a history of cancer.
5. Have significant hearing, visual, or cognitive impairments, or are unable to participate in interviews in a meaningful way.

Primary outcomes:
measure: Objective sleep indicators and clinical sleep-related scales
timeFrame: From enrollment to the end of treatment at 4 weeks
Secondary outcomes:
measure: Resting-state electroencephalogram, resting-state functional magnetic resonance imaging, blood biochemical indicators
timeFrame: From enrollment to the end of treatment at 4 weeks
Other outcomes:
Locations:
city: Suzhou
country: China
facility: Department of Neurology, Second Affiliated Hospital of Soochow University
state: Jiangsu
Study officials:
References:
Clinical trial NCT01460784: STAGES Trial: Study of Adiposity, Growth and Endocrine Stages
Official title: Changes in Adipokines and Adiposity During Puberty and Young Adulthood
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obesity
Keywords: Metabolic dysfunction
Insulin resistance
Brown adipose tissue
Dyslipidemia
Lead sponsor: University of Utah
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2011-10-27
Enrollment: 575
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy, obese young adults

Brief summary: The investigators propose to conduct a cross-sectional study of 60 participants who are 18-30 years of age to undergo research PET/CT. The purpose of this study is to investigate the relationships between Brown Adipose Tissue (BAT), the adiponectin/leptin (A/L) ratio, and components of the metabolic syndrome in young adults.

Detailed description: We propose to conduct a cross-sectional study of 60 participants who are 18-30 years of age to undergo research PET/CT. The purpose of this study is to investigate the relationships between Brown Adipose Tissue (BAT), the adiponectin/leptin (A/L) ratio, and components of the metabolic syndrome in young adults. This study is part of a larger study aimed at understanding the mechanism of brown adipose tissue as a potential protective factor against metabolic dysfunction.

Eligibility criteria: Inclusion Criteria:

* Males and females, 18-30 years of age at enrollment, who are obese (BMI greater or equal to 30 kg/m2, weight less than 159 kg) and healthy
* Without medications and endocrine/genetic disorders known to affect weight.
* Participants may have insulin resistance, impaired glucose tolerance, dyslipidemia, or hypertension.

Exclusion Criteria:

* Anyone who refuses participation.
* A genetic syndrome or other endocrine disorder known to cause obesity (Prader-Willi, Cushing Syndrome, Leptin deficiency, etc.).
* Use of the following medications: psychotropics, sulphonylurea, thiazolidinediones, insulin, glucocorticoids, anti-neoplastic agents, angiotensin receptor blocker, angiotensin-converting enzyme inhibitors.
* Pregnancy or history of pregnancy.
* Active infectious disease
* History of CVD or stroke during the previous 36 months
* Total cholesterol 300 mg/dl, triglycerides 400 mg/dl
* Blood pressure 140/90 mmHg
* Fasting plasma glucose 126 mg/dl.
* Diabetes mellitus, type 1 or 2.

Primary outcomes:
measure: Presence of brown adipose tissue
timeFrame: 2 years
Secondary outcomes:
measure: Presence of metabolic dysfunction
timeFrame: 2 years
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: University of Utah
state: Utah
Study officials:
affiliation: University of Utah, Department of Pediatrics, Division of Adolescent Medicine
name: Nicole Mihalopoulos
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05133284: Effectiveness of a Therapeutic Education Program in Improving Quality of Life of Children With ADHD and Their Parents
Official title: Evaluation of the Effectiveness of the Therapeutic Education Program "Living Better With ADHD" in Improving the Quality of Life of Children With ADHD and Their Parents
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Attention Deficit Disorder
Keywords: Therapeutic Education
Quality of life
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2021-11-24
Enrollment: 24
Sex: ALL
Minimum age (years): 8
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children and adolescents, aged 8 to 13, with a diagnosis of ADHD and participating in the therapeutic education program " Living Well with ADHD "

Brief summary: Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by attention deficit, impulsivity and hyperactivity. It's one of the most frequently encoutered disorder in child psychiatry. ADHD has a significant impact on the quality of life of children and their parents.

In the child psychiatry department of the MPEA Peyre Plantade, a Therapeutic Education program specific to ADHD has been set up for children and their parents. This program consists of different workshops whose aim is to reduce the ADHD repercussions on the daily life of children and their families and thus improve their quality of life.

The principal aim of our study is to evaluate the effectiveness of this program in improving the quality of life of children with ADHD and their parents.


Eligibility criteria: Inclusion criteria:

* Aged 8 to 13
* With a diagnosis of ADHD
* Living in the herault department
* Participatinf in the therapeutic education program " Living Well with ADHD "

Exclusion criteria:

* Parent's objection to the use of data collected
* Parent unable to complete questionnaires

Primary outcomes:
measure: Quality of life of children
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
measure: Quality of life of parents
timeFrame: day 1
measure: Clinical and sociodemiographic characteristics
timeFrame: day 1
Locations:
city: Montpellier
country: France
facility: Uh Montpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Amaria BAGHDADLI, PU-PH
role: STUDY_DIRECTOR
References: